THE EFFECT OF DIOSMIN ON PREVENTING OVARIAN HYPERSTIMULATION SYDROME

Slides:

Advertisements

Similar presentations

Tell The World. McDaniels, A., (2015,September 15) Deaf patients say it can be difficult to communicate at hospitals. The Baltimore Sun. Retrieved from.

Advertisements

中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER 1 夏云飞鼻咽癌Ⅰ b 区淋巴结转移相关危险因素的研究中山大学肿瘤防治中心.

Moderator. To improve the utilization.

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Clarisa R. Gracia, M. D. , M. S. C. E. , Christopher B. Morse, B. A

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

The timeline shows the day of menstrual cycle for a typical patient

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled.

Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

Supplemental PowerPoint Slides

Author Name, Degrees, Affiliation – Helvetica 38pt Bold

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

Headache Script Setting and patient details

Guangzhou Stoma Association

Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase TG Lainas, IA Sfontouris, IZ Zorzovilis, GK Petsas,

Region 8 Flag Status Under Rule

Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment Javier Domingo, M.D., Vicente.

Clarisa R. Gracia, M. D. , M. S. C. E. , Christopher B. Morse, B. A

Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study Arianna D'Angelo, M.D., Rachel.

Patient-tailored ovarian stimulation for in vitro fertilization

Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation Hermann M. Behre, Colin.

Comparison of Metabolic Abnormalities between PCOS Phenotypes A Hospital-based study LI Hui1,2 LI Lin2 YANG Dong-zi2＃ 1 Bupa Medical Center,

Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial

L. G. Maldonado, W. C. Busato, L. M. Rossi, T. C. Bonetti, A

Konstantinos Pantos, M. D. , Evangelos Makrakis, M. D

Aviad Cohen, M.D., Benny Almog, M.D., Togas Tulandi, M.D., M.H.C.M.

Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model Ramiro Quintana, M.D.,

Predicted value of renin activity in a woman who had severe ovarian hyperstimulation syndrome with internal jugular vein thrombosis Fung-Wei Chang, M.D.,

Electroacupuncture decreases the progression of ovarian hyperstimulation syndrome in a rat model Li Chen, Hai-Xiang Sun, You-Bing Xia, Liu-Cai Sui, Ji.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian.

Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials Valeria M.S.

Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa F. Olivennes, G. Trew,

Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis Cui Hong Zheng, M.D., Ph.D.,

Jyotsna Pundir, Sesh Kamal Sunkara, Tarek El-Toukhy, Yacoub Khalaf

A retrospective analysis of ovarian stimulation with letrozole in women undergoing artificial insemination by donor X.J. Sun, L. Jiang, L.C. Ji, R. Nie,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Effect of repeated cryopreservation on human embryo developmental potential Xiaoying Zheng, Yuan Chen, Jie Yan, Yuqi Wu, Xinjie Zhuang, Shengli Lin, Jinliang.

Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model Ofer Fainaru, M.D., Ph.D., Mark D. Hornstein,

Mohamed Fawzy, M. D. , Mohamed Y. AbdelRahman, M. D. , Mohamed H

The effect of protein supplement concentration in embryo transfer medium on clinical outcome of IVF/ICSI cycles: a prospective, randomized clinical trial

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D

Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.

Similarities Differences

Endocrine gland–derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome.

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Significance of metaphase II human oocyte morphology on ICSI outcome

A case of ovarian hyperstimulation syndrome associated with the methylenetetrahydrofolate reductase mutation gene Filippo Ferrara, M.D., Francesco Meli,

Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated.

Sedigheh Borna, M.D., Azita Nasery, M.D. Fertility and Sterility

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

FIG. 22. Experimental comparison XRD diagram

Diane De Neubourg, M. D. , Kathelijne Mangelschots, B. Sc

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome Kris Poppe, M.D., Ph.D., David Unuane,

Presentation transcript:

THE EFFECT OF DIOSMIN ON PREVENTING OVARIAN HYPERSTIMULATION SYDROME Reproductive Medicine Research Center, The Sixth Affiliated Hospital, Sun Yat—sen University, Guangzhou, China ZHU Wan-shan，LI Ting-ting，GUO Ying-chun，FANG Cong

Diosmin group(n=74): Tablet diosmin 1000mg twice a day for a period of 10 days since the day of the retrieval. Control group(n=72): Similar therapy without diosmin.

Comparison of the severity of OHSS Diosmin Group Control Group OHSS(n) 58/74 65/72 Moderate to severe OHSS(n) 5/74* 14/72* Paracentesis(n) 0/5 4/14